ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Majority of Takeda investors want execs to return pay if deals flop

Measure failed to pass but shows shareholder concern over Shire acquisition

Takeda Pharmaceutical CEO Christophe Weber ranks among Japan's highest-paid executives.

TOKYO -- A provision to let Takeda Pharmaceutical claw back executive pay after a major loss or false accounting drew majority support from shareholders even while failing to pass, in a sign of the scrutiny Japan's top drugmaker faces over its roughly $60 billion purchase of Irish peer Shire.

The vote on the shareholder-initiated proposal was disclosed Tuesday in Takeda's report on last week's general meeting.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more